Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study
Table 3
Correlations of estimated in 10-year of major osteoporosis fracture risk, hip fracture risk (FRAX score), and biomarker serum levels.
Estimated 10-year of major osteoporosis fracture risk (FRAX score)
Estimated 10-year of hip fracture risk (FRAX score)
Clinical characteristics and serological features
RA disease duration (yr)
0.230
0.004
0.225
0.005
Menopausal duration (yr)
0.431
<0.001
0.306
<0.001
DAS28 score
-0.003
0.975
0.015
0.857
HAQ-Di score
-0.023
0.777
-0.042
0.607
ESR (mm/hr)
0.261
0.001
0.243
0.002
Rheumatoid factor (UI/mL)
0.061
0.453
0.071
0.377
Tumor necrosis factor-α (pg/mL)
-0.075
0.350
-0.052
0.521
Anti-CCP2 (RU/mL)
0.038
0.641
-0.012
0.882
Anti-MCV (U/mL)
0.082
0.310
0.104
0.198
Treatment characteristics
Glucocorticoid dose (mg)
-0.013
0.876
-0.016
0.838
Biomarker serum levels
Serum sRANKL levels (pmol/L)
0.237
0.003
0.244
0.002
Serum OPG levels (pg/mL)
-0.012
0.881
-0.006
0.942
sRANKL/OPG ratio
0.208
0.009
0.217
0.006
Serum DKK-1 levels (pg/mL)
-0.131
0.104
-0.110
0.173
Serum SOST levels (pg/mL)
-0.240
0.003
-0.209
0.009
Serum OC levels (ng/mL)
-0.059
0.468
-0.029
0.720
Serum CTSK levels (pg/mL)
-0.015
0.848
-0.053
0.515
FRAX: fracture risk assessment tool; DAS28: Disease Activity Score for 28 joints; HAQ-DI: Health Assessment Questionnaire Disability Index; ESR: erythrocyte sedimentation rate; ACPAs: antibodies against cyclic-citrullinated peptides/proteins included anti-CCP2 or anti-MCV; sRANKL: Soluble Receptor Activator for Nuclear Factor kappa B Ligand; OPG: osteoprotegerin; DKK-1: Dickkopf-1; SOST: sclerostin; OC: osteocalcin; CTSK: cathepsin k. Correlations between biomarker serum levels and FRAX indices were performed using Pearson test.
